Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Adding Venetoclax to Chemo for Young Patients With AML

01/07/2021

Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.

Jeffrey Rubnitz, MD, PhD,...

01/07/2021

Oncology

Videos

Hot Topics in AML from the Virtual 2020 Lymphoma, Leukemia and Myeloma Congress

10/24/2020

Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.

Gail J. Roboz, MD, summarizes...

10/24/2020

Oncology

Podcasts

Abhishek Maiti, MBBS, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML

10/15/2020

Dr Maiti discusses findings from a trial of 10-day decitabine plus venetoclax for patients with newly diagnosed, intensive chemo–ineligible, and relapsed/refractory AML.

Dr Maiti discusses findings from...

10/15/2020

Oncology

Podcasts

Dr Percival Discusses New Treatments in the AML Space

09/21/2020

Mary-Beth Pervical, MD, Seattle Cancer Care Alliance, discusses novel treatments for patients with acute myeloid leukemia.

Mary-Beth Pervical, MD, Seattle...

09/21/2020

Oncology

Videos

Mary-Beth Percival, MD, on the Current State of the AML Treatment Landscape

09/21/2020

Dr Percival provides her insight on how the treatment landscape has evolved thus far for patients with AML, and therapies that are currently in the pipeline.

Dr Percival provides her insight...

09/21/2020

Oncology

Videos

Onvansertib Combined With Standard-Care Chemo Safe, Well-Tolerated in AML

09/19/2020

Amer Zeidan, MBBS, discusses a trial exploring onvansertinib plus standard-of-care chemo in patients with AML.

Amer Zeidan, MBBS, discusses a...

09/19/2020

Oncology

Videos

Venetoclax Added to Azacitidine Improves Responses, OS in Older Patients With AML

07/15/2020

Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.

Courtney DiNardo, MD, discusses...

07/15/2020

Oncology

Videos

Gail Roboz, MD, Hints at Topics in AML, ALL Being Debated and Addressed

06/14/2020

Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.

Dr Roboz gives attendees a taste...

06/14/2020

Oncology

Podcasts

Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML

05/31/2020

Courtney DiNardo, MD, MSCE, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated AML.

Courtney DiNardo, MD, MSCE,...

05/31/2020

Oncology

$Triplet Combination Yields Encouraging Responses, OS in Relapsed/ Refractory AML$

Videos

Triplet Combination Yields Encouraging Responses, OS in Relapsed/ Refractory AML

03/19/2020

Naval Daver, MD, discusses the results of a phase 2 study exploring azacitidine plus nivolumab and ipilimumab for patients with relapsed/refractory AML.

Naval Daver, MD, discusses the...

03/19/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology